Recent developments in multiple sclerosis therapeutics

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally considered to be an inflammatory, autoimmune, demyelinating disease of the central nervous system. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. These approaches, including high-dose corticosteroids for acute relapses and long-term use of parenteral interferon-β, glatiramer acetate or natalizumab for disease modification, are at best moderately effective. Growing evidence supports that, while an inflammatory pathology characterizes the early relapsing stage of multiple sclerosis, neurodegenerative pathology dominates the later progressive stage of the disease. Multiple sclerosis disease-modifying therapies currently in development attempt to specifically target the underlying pathology at each stage of the disease, while avoiding frequent self-injection. These include a variety of oral medications and monoclonal antibodies to reduce inflammation in relapsing multiple sclerosis and agents intended to promote neuroprotection and neurorepair in progressive multiple sclerosis. Although newer therapies for relapsing MS have the potential to be more effective and easier to administer than current therapies, they also carry greater risks. Effective treatments for progressive multiple sclerosis are still being sought.2009 Spain et al; licensee BioMed Central Ltd.

Original languageEnglish (US)
Article number74
JournalBMC Medicine
Volume7
DOIs
StatePublished - Dec 7 2009

Fingerprint

Multiple Sclerosis
Pathology
CNS Demyelinating Autoimmune Diseases
Therapeutics
Inflammation
Nervous System Diseases
Interferons
Young Adult
Adrenal Cortex Hormones
Monoclonal Antibodies
Recurrence
Injections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recent developments in multiple sclerosis therapeutics. / Spain, Rebecca; Cameron, Michelle; Bourdette, Dennis.

In: BMC Medicine, Vol. 7, 74, 07.12.2009.

Research output: Contribution to journalArticle

@article{ce01a61b288644b0a69f8c565835c140,
title = "Recent developments in multiple sclerosis therapeutics",
abstract = "Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally considered to be an inflammatory, autoimmune, demyelinating disease of the central nervous system. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. These approaches, including high-dose corticosteroids for acute relapses and long-term use of parenteral interferon-β, glatiramer acetate or natalizumab for disease modification, are at best moderately effective. Growing evidence supports that, while an inflammatory pathology characterizes the early relapsing stage of multiple sclerosis, neurodegenerative pathology dominates the later progressive stage of the disease. Multiple sclerosis disease-modifying therapies currently in development attempt to specifically target the underlying pathology at each stage of the disease, while avoiding frequent self-injection. These include a variety of oral medications and monoclonal antibodies to reduce inflammation in relapsing multiple sclerosis and agents intended to promote neuroprotection and neurorepair in progressive multiple sclerosis. Although newer therapies for relapsing MS have the potential to be more effective and easier to administer than current therapies, they also carry greater risks. Effective treatments for progressive multiple sclerosis are still being sought.2009 Spain et al; licensee BioMed Central Ltd.",
author = "Rebecca Spain and Michelle Cameron and Dennis Bourdette",
year = "2009",
month = "12",
day = "7",
doi = "10.1186/1741-7015-7-74",
language = "English (US)",
volume = "7",
journal = "BMC Medicine",
issn = "1741-7015",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Recent developments in multiple sclerosis therapeutics

AU - Spain, Rebecca

AU - Cameron, Michelle

AU - Bourdette, Dennis

PY - 2009/12/7

Y1 - 2009/12/7

N2 - Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally considered to be an inflammatory, autoimmune, demyelinating disease of the central nervous system. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. These approaches, including high-dose corticosteroids for acute relapses and long-term use of parenteral interferon-β, glatiramer acetate or natalizumab for disease modification, are at best moderately effective. Growing evidence supports that, while an inflammatory pathology characterizes the early relapsing stage of multiple sclerosis, neurodegenerative pathology dominates the later progressive stage of the disease. Multiple sclerosis disease-modifying therapies currently in development attempt to specifically target the underlying pathology at each stage of the disease, while avoiding frequent self-injection. These include a variety of oral medications and monoclonal antibodies to reduce inflammation in relapsing multiple sclerosis and agents intended to promote neuroprotection and neurorepair in progressive multiple sclerosis. Although newer therapies for relapsing MS have the potential to be more effective and easier to administer than current therapies, they also carry greater risks. Effective treatments for progressive multiple sclerosis are still being sought.2009 Spain et al; licensee BioMed Central Ltd.

AB - Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally considered to be an inflammatory, autoimmune, demyelinating disease of the central nervous system. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. These approaches, including high-dose corticosteroids for acute relapses and long-term use of parenteral interferon-β, glatiramer acetate or natalizumab for disease modification, are at best moderately effective. Growing evidence supports that, while an inflammatory pathology characterizes the early relapsing stage of multiple sclerosis, neurodegenerative pathology dominates the later progressive stage of the disease. Multiple sclerosis disease-modifying therapies currently in development attempt to specifically target the underlying pathology at each stage of the disease, while avoiding frequent self-injection. These include a variety of oral medications and monoclonal antibodies to reduce inflammation in relapsing multiple sclerosis and agents intended to promote neuroprotection and neurorepair in progressive multiple sclerosis. Although newer therapies for relapsing MS have the potential to be more effective and easier to administer than current therapies, they also carry greater risks. Effective treatments for progressive multiple sclerosis are still being sought.2009 Spain et al; licensee BioMed Central Ltd.

UR - http://www.scopus.com/inward/record.url?scp=73149094510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73149094510&partnerID=8YFLogxK

U2 - 10.1186/1741-7015-7-74

DO - 10.1186/1741-7015-7-74

M3 - Article

VL - 7

JO - BMC Medicine

JF - BMC Medicine

SN - 1741-7015

M1 - 74

ER -